Iovance Biotherapeutics is a commercial-stage biopharmaceutical company specializing in tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers. Its two commercial products are Amtagvi (lifileucel), the first FDA-approved one-time individualized T cell therapy for previously treated advanced melanoma, and Proleukin (aldesleukin), an IL-2 product used in the Amtagvi treatment regimen. The company conducts centralized, scalable manufacturing and has ongoing registrational trials in frontline melanoma and non-small cell lung cancer.
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001104659-26-018899 | EDGAR | 118K words |
| 2025-02-27 | 2024-12-31 | 0001558370-25-001834 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001558370-24-002036 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001558370-23-002419 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001976 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001558370-21-001858 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001104659-20-024830 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001144204-19-010702 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001144204-18-014151 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001144204-17-013535 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001104659-25-107470 | EDGAR | 87K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010807 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001558370-25-007009 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014905 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011641 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007646 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-018029 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001558370-23-013988 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009134 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001558370-22-016295 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001558370-22-012263 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001558370-22-007449 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-20 | 0001104659-26-032774 | EDGAR | 1K words |
| 2026-02-24 | 0001104659-26-018837 | EDGAR | — |
| 2026-01-09 | 0001104659-26-002323 | EDGAR | — |
| 2025-11-06 | 0001104659-25-107426 | EDGAR | — |
| 2025-08-29 | 0001104659-25-085650 | EDGAR | — |
| 2025-08-22 | 0001104659-25-081953 | EDGAR | — |
| 2025-08-19 | 0001104659-25-080304 | EDGAR | — |
| 2025-08-07 | 0001104659-25-075175 | EDGAR | — |
| 2025-07-15 | 0001104659-25-067940 | EDGAR | — |
| 2025-07-03 | 0001104659-25-065781 | EDGAR | — |
389 total filings indexed. 357 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001425205 |
| Ticker | IOVA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.iovance.com |
| Listed | 2010-05-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report